Briacell Therapeutics Corp BCTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:00 AM EDT
2.80quote price arrow up+0.13 (+4.69%)
Volume
4,226
52 week range
2.19 - 7.65
Loading...
  • Open2.64
  • Day High2.81
  • Day Low2.60
  • Prev Close2.67
  • 52 Week High7.65
  • 52 Week High Date04/03/23
  • 52 Week Low2.19
  • 52 Week Low Date03/21/24

Key Stats

  • Market Cap40.22M
  • Shares Out15.98M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-54.19

KEY STATS

  • Open2.64
  • Day High2.81
  • Day Low2.60
  • Prev Close2.67
  • 52 Week High7.65
  • 52 Week High Date04/03/23
  • 52 Week Low2.19
  • 52 Week Low Date03/21/24
  • Market Cap40.22M
  • Shares Out15.98M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-54.19

RATIOS/PROFITABILITY

  • EPS (TTM)-0.81
  • P/E (TTM)-3.43
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date06/10/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Briacell Therapeutics Corp

 

Profile

MORE
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The...
Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
William Williams M.D.
President, Chief Executive Officer, Director
Gadi Levin
Chief Financial Officer, Corporate Secretary
Address
3rd Floor
Bellevue Centre,, 235-15th Str
West Vancouver, BC
V7T 2X1
Canada